Company Profile

Adjuvax LLC
Profile last edited on: 10/9/23      CAGE: 8RK88      UEI: EGVNJG3GMEL7

Business Identifier: Novel saponin-based vaccine adjuvants as practical alternative to well-established /FDA-approved saponin adjuvant QS-21
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

622 Renaissance Drive
Hoover, AL 35226
   (205) 936-0770
Location: Single
Congr. District: 06
County: Jefferson

Public Profile

A vaccine ingredient that helps evoke a stronger immune response, "Adjuvants" may constitute an indispensable element of modern vaccines by enhancing the ability of a vaccine to (1) elicit strong and durable immune responses -- including in immunologically compromised individuals -- r(2) reduce the antigen dose and the number of immunizations, and (3) modulate the nature of immune response to specific pathogens. Despite the increasingly important role of adjuvants in modern vaccination, only a few adjuvants have so farbeen FDA approved for human use. Among them, QS-21, a natural product isolated from the tree bark of Quillaja Saponaria Molina, an evergreen tree native to temperate central Chile, is deemed a gold standard of immunostimulants, owing to its excellence in potentiating a balanced Th1/Th2 immune response with antigen-specific CTL production, which makes it an ideal choice for vaccines against intracellular pathogens as well as for therapeutic cancer vaccines. Adjuvax LLC focuses on developing novel saponin-based vaccine adjuvants from natural resources other than Quillaja saponaria Molina, to circumvent ecological damage and supply shortage due to its overexploitation. Adjuvax LLCÂ’s solution is a pair of VSA saponin adjuvants prepared in one step from Momordica saponins isolated from widely available seeds of Momordica cochinchinensis SPRENG (MC), a perennial vine. Immunological evaluations have demonstrated that just like QS-21, VSA adjuvants induce a strong antigen-specific, mixed Th1/Th2 immune response. Moreover, the VSA adjuvants are much less toxic than QS-21 and compatible with different adjuvant combination and formulation techniques

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 1 NIH $600,000
Project Title: Development of AS01b Mimics by Replacing QS-21 with a New Saponin Adjuvant
2022 1 NIH $600,000
Project Title: Optimize Formulation of VSA Adjuvant

Key People / Management

  Weiwei Li -- Chief Financial Officer

  Suzanne Michalek -- Chief Technology Oficer

  Pengfei Wang -- Chief Scientific Officer

  Yu Zhao -- Chief Executive Officer

Company News

There are no news available.